

## PHILIP MORRIS INTERNATIONAL INC.

### FORM 8-K (Current report filing)

## Filed 12/12/25 for the Period Ending 12/12/25

Address 677 WASHINGTON BLVD, STE. 1100

STAMFORD, CT, 06901

Telephone 203-905-2410

CIK 0001413329

Symbol PM

SIC Code 2111 - Cigarettes

Industry Tobacco

Sector Consumer Non-Cyclicals

Fiscal Year 12/31

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 12, 2025

## Philip Morris International Inc.

(Exact name of registrant as specified in its charter)

Virginia
(State or other jurisdiction of incorporation)

1-33708 (Commission File Number) 13-3435103 (I.R.S. Employer Identification No.)

677 Washington Blvd,

Ste. 1100 Stamford

rd Connecticut

06901

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (203) 905-2410

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| Ш | written communications pursuant to Rule 423 under the Securities Act (17 CFR 230.423)                  |
|---|--|
|   | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)                 |
|   | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|   | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class        | Trading Symbol(s) | Name of each exchange on which registered |
|----------------------------|-------------------|---|
| Common Stock, no par value | PM                | New York Stock Exchange                   |
| 2.750% Notes due 2026      | PM26A             | New York Stock Exchange                   |
| 2.875% Notes due 2026      | PM26              | New York Stock Exchange                   |
| 0.125% Notes due 2026      | PM26B             | New York Stock Exchange                   |
| 3.125% Notes due 2027      | PM27              | New York Stock Exchange                   |
| 3.125% Notes due 2028      | PM28              | New York Stock Exchange                   |
| 2.875% Notes due 2029      | PM29              | New York Stock Exchange                   |
| 3.375% Notes due 2029      | PM29A             | New York Stock Exchange                   |
| 2.750% Notes due 2029      | PM29D             | New York Stock Exchange                   |
| 3.750% Notes due 2031      | PM31B             | New York Stock Exchange                   |
| 0.800% Notes due 2031      | PM31              | New York Stock Exchange                   |
| 3.250% Notes due 2032      | PM32              | New York Stock Exchange                   |
| 3.125% Notes due 2033      | PM33              | New York Stock Exchange                   |
| 2.000% Notes due 2036      | PM36              | New York Stock Exchange                   |
| 1.875% Notes due 2037      | PM37A             | New York Stock Exchange                   |
| 6.375% Notes due 2038      | PM38              | New York Stock Exchange                   |
| 1.450% Notes due 2039      | PM39              | New York Stock Exchange                   |
| 4.375% Notes due 2041      | PM41              | New York Stock Exchange                   |
| 4.500% Notes due 2042      | PM42              | New York Stock Exchange                   |
| 3.875% Notes due 2042      | PM42A             | New York Stock Exchange                   |
| 4.125% Notes due 2043      | PM43              | New York Stock Exchange                   |
| 4.875% Notes due 2043      | PM43A             | New York Stock Exchange                   |
| 4.250% Notes due 2044      | PM44              | New York Stock Exchange                   |

| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).             |  |
|--|--|
| Emerging growth company  |  |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

#### Item 7.01. Regulation FD Disclosure.

On December 12, 2025, Philip Morris International Inc. issued a press release announcing that its Board of Directors declared a regular quarterly dividend of \$1.47 per common share, which press release is attached as Exhibit 99.1 to this Item 7.01 of this Current Report on Form 8-K and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference in such filing or document.

| Item 9.01. | Financial Statements and Exhibits.  |
|------------|---|
|            |   |
| (d)        | Exhibits.   |
| 99.1       | Philip Morris International Inc. Press Release, dated December 12, 2025 (furnished pursuant to Item 7.01).                            |
| 104        | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document and contained in Exhibit 101) |
|            |   |

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### PHILIP MORRIS INTERNATIONAL INC.

By: <u>/s/ DARLENE QUASHIE HENRY</u>

Name: Darlene Quashie Henry

Title: Vice President, Associate General Counsel & Corporate

Secretary

Date: December 12, 2025

## PHILIP MORRIS INTERNATIONAL

#### **PRESS RELEASE**

Investor Relations: Stamford, CT: +1 (203) 905 2413 Email: InvestorRelations@pmi.com Media: Corey Henry Lausanne: +41 (0)58 242 4500 Stamford, CT: +1 (203) 905 2410 Email: Corey.Henry@pmi.com

## Philip Morris International Declares Regular Quarterly Dividend of \$1.47 Per Share

STAMFORD, CT, December 12, 2025 – The Board of Directors of Philip Morris International Inc. (NYSE: PM) today declared a regular quarterly dividend of \$1.47 per common share, payable on January 14, 2026, to shareholders of record as of December 26, 2025. The ex-dividend date is December 26, 2025. For more details on stock, dividends and other information, see <a href="https://www.pmi.com/dividend">www.pmi.com/dividend</a>.

#### Philip Morris International: A Global Smoke-Free Champion

Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Our smoke-free products are available for sale in over 100 markets, and as of June 30, 2025 PMI estimates they were used by over 41 million legal-age consumers around the world, many of whom have moved away from cigarettes or significantly reduced their consumption. The smoke-free business accounted for 41% of PMI's first-nine months 2025 total net revenues. Since 2008, PMI has invested over \$14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's *General* snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit www.pmi.com and wwww.pmi.com and www.pmi.com.